Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.32

+0.7%

Nov 5 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1003)	9/16/2001 8:53:40 PM
From: Arthur Radley	Read Replies (1) of 1475

What a tragic week for our nation! I wonder if this conference will take place this week and if BTRN will make their presentation... "We are pleased that siplizumab appears to be safe and well tolerated and is having a clinically meaningful and durable impact on patients' psoriatic disease,'' said James F. Young, Ph.D., MedImmune's president, research and development. ``We currently have a broad Phase II program underway and expect to provide additional data from our Phase I program later this year at the European Society of Dermatological Research Meeting to be held September 20 - 22, 2001 in Stockholm, Sweden.''

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next